Dr David Preiss
- Honorary Clinical Senior Lecturer (School of Cardiovascular & Metabolic Health)
https://orcid.org/0000-0003-3139-1836Publications
2023
Mayne, K. J. et al. (2023) Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease. Journal of the American Society of Nephrology, (doi: 10.1681/ASN.0000000000000271) (PMID:38082486) (Early Online Publication)
2020
Coll, A. P. et al. (2020) GDF15 mediates the effects of metformin on body weight and energy balance. Nature, 578, pp. 444-448. (doi: 10.1038/s41586-019-1911-y) (PMID:31875646) (PMCID:PMC7234839)
2019
Sattar, N. and Preiss, D. (2019) Research digest: new horizons in heart failure therapy. Lancet Diabetes and Endocrinology, 7(11), p. 832. (doi: 10.1016/S2213-8587(19)30315-8) (PMID:31621593)
Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)
Welsh, P. et al. (2019) Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes. Circulation, 139(24), pp. 2754-2764. (doi: 10.1161/CIRCULATIONAHA.118.038529) (PMID:31014085) (PMCID:PMC6571179)
2018
Welsh, P. et al. (2018) Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clinical Chemistry, 64(11), pp. 1607-1616. (doi: 10.1373/clinchem.2018.292086) (PMID:30126950)
2017
Sattar, N. , Toth, P. P., Blom, D. J., Koren, M. J., Soran, H., Uhart, M., Elliott, M., Cyrille, M., Somaratne, R. and Preiss, D. (2017) Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus. American Journal of Cardiology, 120(9), pp. 1521-1527. (doi: 10.1016/j.amjcard.2017.07.047) (PMID:28844508)
Sattar, N. and Preiss, D. (2017) Reverse causality in cardiovascular epidemiological research: more common than imagined? Circulation, 135(24), pp. 2369-2372. (doi: 10.1161/CIRCULATIONAHA.117.028307) (PMID:28606949)
Toth, P. P. et al. (2017) Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation, 135(19), pp. 1819-1831. (doi: 10.1161/CIRCULATIONAHA.116.025233) (PMID:28249876)
Preiss, D. et al. (2017) Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 19(3), pp. 356-363. (doi: 10.1111/dom.12826) (PMID:27862873) (PMCID:PMC5330429)
Schmidt, A. F. et al. (2017) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes and Endocrinology, 5(2), pp. 97-105. (doi: 10.1016/S2213-8587(16)30396-5) (PMID:27908689) (PMCID:PMC5266795)
Kristensen, S. L. et al. (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve). Circulation, 135(8), pp. 724-735. (doi: 10.1161/CIRCULATIONAHA.116.024593) (PMID:28052977)
2016
Preiss, D. , Rankin, N. , Welsh, P. , Holman, R.R., Kangas, A.J., Soininen, P., Würtz, P., Ala-Korpela, M. and Sattar, N. (2016) Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study. Diabetic Medicine, 33(11), pp. 1569-1574. (doi: 10.1111/dme.13097) (PMID:26887663)
Preiss, D. and Sattar, N. (2016) Research digest: cardiac biomarkers for risk prediction. Lancet Diabetes and Endocrinology, 4(11), p. 890. (doi: 10.1016/S2213-8587(16)30293-5) (PMID:27743976)
Sattar, N. , Logue, J. and Preiss, D. (2016) Research digest: weight loss to prevent and treat diabetes. Lancet Diabetes and Endocrinology, 4(10), p. 817. (doi: 10.1016/S2213-8587(16)30244-3) (PMID:27663958)
Currie, G. et al. (2016) Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology, 17, 127. (doi: 10.1186/s12882-016-0337-0) (PMID:27609359) (PMCID:PMC5015203)
Preiss, D. and Sattar, N. (2016) Research digest: NAFLD in the spotlight. Lancet Diabetes and Endocrinology, 4(9), p. 735. (doi: 10.1016/S2213-8587(16)30187-5) (PMID:27480034)
Preiss, D. , Welsh, P. and Sattar, N. (2016) Metformin therapy and circulating NT-proBNP levels: the CAMERA trial. Diabetes Care, 39(8), e114-e115. (doi: 10.2337/dc16-0887) (PMID:27271181)
Sattar, N. and Preiss, D. (2016) Research digest. Lancet Diabetes and Endocrinology, 4(8), p. 651. (doi: 10.1016/S2213-8587(16)30161-9) (PMID:27401823)
Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J.V. (2016) SGLT2 and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1333-1339. (doi: 10.1007/s00125-016-3956-x) (PMID:27112340) (PMCID:PMC4901113)
Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J. (2016) Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1573-1574. (doi: 10.1007/s00125-016-3987-3) (PMID:27174369) (PMCID:PMC4969788)
Sattar, N. and Preiss, D. (2016) Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure. Lancet Diabetes and Endocrinology, 4(7), pp. 555-556. (doi: 10.1016/s2213-8587(16)30097-3) (PMID:27216887)
Sattar, N. and Preiss, D. (2016) Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing. Lancet Diabetes and Endocrinology, 4(7), pp. 560-562. (doi: 10.1016/S2213-8587(16)00085-1) (PMID:27039357)
Nissen, S. E. et al. (2016) Efficacy and tolerability of evolocumab vs. ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA: Journal of the American Medical Association, 315(15), pp. 1580-1590. (doi: 10.1001/jama.2016.3608) (PMID:27039291)
Loomis, A. K. et al. (2016) Body mass index and risk of non-alcoholic fatty liver disease: two electronic health record prospective studies. Journal of Clinical Endocrinology and Metabolism, 101(3), pp. 945-952. (doi: 10.1210/jc.2015-3444) (PMID:26672639) (PMCID:PMC4803162)
Goldie, C., Taylor, A. J., Nguyen, P., McCoy, C., Zhao, X.-Q. and Preiss, D. (2016) Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials. Heart, 102(3), pp. 198-203. (doi: 10.1136/heartjnl-2015-308055) (PMID:26370223)
Welsh, P. et al. (2016) Prediction of cardiovascular disease risk by cardiac biomarkers in 2 United Kingdom cohort studies: does utility depend on risk thresholds for treatment? Hypertension, 2016(67), pp. 309-315. (doi: 10.1161/HYPERTENSIONAHA.115.06501) (PMID:26667414) (PMCID:PMC4716288)
Kristensen, S. L. et al. (2016) Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure, 9(1), e002560. (doi: 10.1161/CIRCHEARTFAILURE.115.002560) (PMID:26754626) (PMCID:PMC4718182)
Jackson, C. E. et al. (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 18(12), pp. 1491-1498. (doi: 10.1002/ejhf.543) (PMID:27114189)
Rankin, N. J. , Preiss, D. , Welsh, P. and Sattar, N. (2016) Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future. International Journal of Epidemiology, 45(5), pp. 1351-1371. (doi: 10.1093/ije/dyw271) (PMID:27789671) (PMCID:PMC5100629)
Sattar, N. , Preiss, D. , Robinson, J. G., Djedjos, C. S., Elliott, M., Somaratne, R., Wasserman, S. M. and Raal, F. J. (2016) Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes and Endocrinology, 4(5), pp. 403-410. (doi: 10.1016/S2213-8587(16)00003-6) (PMID:26868195)
2015
Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi: 10.1016/j.jchf.2015.03.014) (PMID:26251088)
Preiss, D. et al. (2015) Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 5(8), e007901. (doi: 10.1136/bmjopen-2015-007901) (PMID:26275900) (PMCID:PMC4550730)
Rush, C. J., Campbell, R. T., Jhund, P. S. , Connolly, E. C., Preiss, D. , Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC: Heart Failure, 3(8), pp. 603-614. (doi: 10.1016/j.jchf.2015.03.013) (PMID:26251086)
Yates, T. et al. (2015) Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabetic Medicine, 32(8), pp. 1090-1096. (doi: 10.1111/dme.12762) (PMID:25818859)
Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi: 10.1093/eurheartj/ehv072) (PMID:25802390) (PMCID:PMC4769322)
Preiss, D. and Kristensen, S. L. (2015) The new Pooled cohort equations risk calculator. Canadian Journal of Cardiology, 31(5), pp. 613-619. (doi: 10.1016/j.cjca.2015.02.001) (PMID:25843167)
Kristensen, S. L. et al. (2015) Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 17(2), pp. 169-176. (doi: 10.1002/ejhf.211) (PMID:25756844)
Preiss, D. and Sattar, N. (2015) Classification of reported statin intolerance. Current Opinion in Lipidology, 26(1), pp. 65-66. (doi: 10.1097/MOL.0000000000000149) (PMID:25551804)
Swerdlow, D. I. et al. (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, 385(9965), pp. 351-361. (doi: 10.1016/S0140-6736(14)61183-1) (PMID:25262344) (PMCID:PMC4322187)
Preiss, D. and Sattar, N. (2015) Does the LDL receptor play a role in the risk of developing type 2 diabetes? JAMA: Journal of the American Medical Association, 313(10), pp. 1016-1017. (doi: 10.1001/jama.2015.1275) (PMID:25756436)
Sattar, N. , Welsh, P. and Preiss, D. (2015) The insulin resistance syndrome. In: DeFronzo, R. A., Ferrannini, E., Alberti, K.G.M.M. and Zimmet, P. (eds.) International Textbook of Diabetes Mellitus. John Wiley & Sons, Ltd, pp. 337-353. ISBN 9781118387658 (doi: 10.1002/9781118387658.ch23)
Welsh, P. , Preiss, D. and Touyz, R. M. (2015) Biomarkers of hypertension and cardiovascular disease. In: Peplow, P., Adams, J. and Young, T. (eds.) Cardiovascular and Metabolic Disease: Scientific Discoveries and New Therapies. Series: RSC Drug discovery series. Royal Society of Chemistry, pp. 117-136. ISBN 9781782620464 (doi: 10.1039/9781782622390-00117)
Welsh, P. , Preiss, D. , Tsiropoulou, S., Rios, F. J. , Harvey, A., Dulak-Lis, M. G., Montezano, A. C. and Touyz, R. M. (2015) Biomarkers of vascular inflammation and cardiovascular disease. In: Berbari, A. and Mancia, G. (eds.) Arterial Disorders: Definition, Clinical Manifestations, Mechanisms and Therapeutic Approaches. Springer: Cham, pp. 115-136. ISBN 9783319145556 (doi: 10.1007/978-3-319-14556-3_9)
2014
Preiss, D. et al. (2014) Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 16(12), pp. 1265-1268. (doi: 10.1111/dom.12320) (PMID:24861892)
Welsh, P. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 57(12), pp. 2513-2520. (doi: 10.1007/s00125-014-3383-9) (PMID:25264116)
Preiss, D. (2014) Do statins reduce microvascular complications in diabetes? Lancet Diabetes and Endocrinology, 2(11), pp. 858-859. (doi: 10.1016/S2213-8587(14)70177-9) (PMID:25217179)
Preiss, D. , McMurray, J. J. and Sattar, N. (2014) Treatment of severe hypertriglyceridaemia. Lancet Diabetes and Endocrinology, 2(11), p. 860. (doi: 10.1016/s2213-8587(14)70052-x) (PMID:25439459)
Rankin, N. J. , Preiss, D. , Welsh, P. , Burgess, K. E.V., Nelson, S. M. , Lawlor, D. A. and Sattar, N. (2014) The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis, 237(1), pp. 287-300. (doi: 10.1016/j.atherosclerosis.2014.09.024) (PMID:25299963) (PMCID:PMC4232363)
Preiss, D. and Packard, C. J. (2014) Emerging therapeutic approaches to treat dyslipidemia. Current Cardiology Reports, 16(7), (doi: 10.1007/s11886-014-0506-3) (PMID:24890766)
Preiss, D. , Lloyd, S. M. , Ford, I. , McMurray, J. J.V. , Holman, R. R., Welsh, P. , Fisher, M., Packard, C. J. and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi: 10.1016/S2213-8587(13)70152-9) (PMID:24622715)
Sattar, N. , Forrest, E. and Preiss, D. (2014) Non-alcoholic fatty liver disease. British Medical Journal, 2014(349), g4596. (doi: 10.1136/bmj.g4596) (PMID:25239614) (PMCID:PMC4168663)
2013
Preiss, D. and Sattar, N. (2013) Choice of medical therapy to lower triglycerides in those at risk of pancreatitis. Current Opinion in Lipidology, 24(6), pp. 532-533. (doi: 10.1097/MOL.0000000000000029)
Perez, A.C., Jhund, P. , Preiss, D. , Kjekshus, J. and McMurray, J.J.V. (2013) Effect of rosuvastatin on fatigue in patients with heart failure. Journal of the American College of Cardiology, 61(10), pp. 1121-1122. (doi: 10.1016/j.jacc.2012.12.004)
Preiss, D. (2013) Triglyceride levels, pancreatitis and choice of lipid-modifying therapy. Expert Review of Gastroenterology and Hepatology, 7(3), pp. 193-195. (doi: 10.1586/EGH.12.79)
Preiss, D. et al. (2013) Predictors of stroke in patients with impaired glucose tolerance: results from the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. Stroke, 44(9), pp. 2590-2593. (doi: 10.1161/STROKEAHA.113.001177)
2012
Preiss, D. et al. (2012) Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2(6), e001925. (doi: 10.1136/bmjopen-2012-001925)
Preiss, D. et al. (2012) Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA: Journal of the American Medical Association, 308(8), pp. 804-811. (doi: 10.1001/jama.2012.8439)
Preiss, D. (2012) Statin therapy and new-onset diabetes: a cause for concern? Maturitas, 72(2), pp. 95-96. (doi: 10.1016/j.maturitas.2012.02.014)
Preiss, D. and Sattar, N. (2012) Pharmacotherapy: statins and new-onset diabetes—the important questions. Nature Reviews Cardiology, 9(4), pp. 190-192. (doi: 10.1038/nrcardio.2012.15)
Preiss, D. et al. (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 14(8), pp. 909-915. (doi: 10.1093/eurjhf/hfs067)
Sattar, N. and Preiss, D. (2012) HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. Diabetologia, 55(6), pp. 1564-1567. (doi: 10.1007/s00125-012-2510-8)
2011
Ford, I. et al. (2011) The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International Journal of Epidemiology, 40(6), pp. 1530-1538. (doi: 10.1093/ije/dyr172)
Shyangdan, D., Clar, C., Ghouri, N. , Henderson, R., Gurung, T., Preiss, D. , Sattar, N. , Fraser, A. and Waugh, N. (2011) Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technology Assessment, 15(38), pp. 1-110. (doi: 10.3310/hta15380)
Preiss, D. , Sesashai, S.R.K. and Ray, K.K. (2011) Statin therapy dose and risk of new-onset diabetes: reply. JAMA: Journal of the American Medical Association, 306(12), p. 1326. (doi: 10.1001/jama.2011.1355)
Preiss, D. and Ray, K.K. (2011) Intensive glucose lowering treatment in type 2 diabetes. British Medical Journal, 343, d4243. (doi: 10.1136/bmj.d4243)
Ghouri, N. A. , Preiss, D. and Sattar, N. (2011) Reply (Need for a Three-Focused Approach to Nonalcoholic Fatty Liver Disease). Hepatology, 53(5), p. 1774. (doi: 10.1002/hep.24138)
Preiss, D. , Khunti, K. and Sattar, N. (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabetic Medicine, 28(1), pp. 19-22. (doi: 10.1111/j.1464-5491.2010.03157.x)
Preiss, D. and Sattar, N. (2011) The case for diabetes screening: ADDITION-Europe. Lancet, 378(9786), pp. 106-108. (doi: 10.1016/S0140-6736(11)60819-2)
Preiss, D. and Sattar, N. (2011) Statins and the risk of new-onset diabetes: a review of recent evidence. Current Opinion in Lipidology, 22(6), pp. 460-466. (doi: 10.1097/MOL.0b013e32834b4994)
Preiss, D. , Sattar, N. and McMurray, J.J. (2011) A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. American Heart Journal, 161(1), p. 210. (doi: 10.1016/j.ahj.2010.10.019)
Preiss, D. et al. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA: Journal of the American Medical Association, 305(24), pp. 2556-2564. (doi: 10.1001/jama.2011.860)
2010
Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi: 10.1016/S0140-6736(09)61965-6)
Preiss, D. , Sattar, N. and McMurray, J.J. (2010) Event rates in trials of patients with Type 2 diabetes. JAMA: Journal of the American Medical Association, 303(8), pp. 732-733. (doi: 10.1001/jama.2010.137)
Ghouri, N. , Preiss, D. and Sattar, N. (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology, 52(3), pp. 1156-1161. (doi: 10.1002/hep.23789)
Preiss, D. and Sattar, N. (2010) HbA1c: a useful cardiovascular risk marker in those without diabetes? Diabetologia, 53(12), pp. 2468-2469. (doi: 10.1007/s00125-010-1902-x)
Preiss, D. , Welsh, P. , Murray, H., Shepherd, J., Packard, C. , Macfarlane, P., Cobbe, S., Ford, I. and Sattar, N. (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up(dagger). European Heart Journal, 31(10), pp. 1230-1236. (doi: 10.1093/eurheartj/ehq095)
Sattar, N. , Preiss, D. , Welsh, P. , Seshasai, S.R.K. and Ray, K.K. (2010) Statins and risk of incident diabetes Reply. Lancet, 375(9732), pp. 2141-2142.
2009
Preiss, D. et al. (2009) Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920. (doi: 10.2337/dc08-1709) (PMID:19196892)
Preiss, D.J. and Sattar, N.A. (2009) Metformin and lactic acidosis Metformin: framed again? British Medical Journal, 339, b5570. (doi: 10.1136/bmj.b5570)
Preiss, D. and Sattar, N. (2009) Authors' reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. Clinical Endocrinology, 71(3), pp. 456-457.
Preiss, D. and Sattar, N. (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology, 70(6), pp. 815-828.
Preiss, D. and Sattar, N. (2009) Metabolic syndrome: collapsing under its own weight? Diabetic Medicine, 26(5), pp. 457-459.
Preiss, D. et al. (2009) Predictors of Development in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920.
Ray, K., Seshasai, S., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D. , Erqou, S. and Sattar, N. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 373(9677), pp. 1765-1772. (doi: 10.1016/S0140-6736(09)60697-8)
2008
Preiss, D. , Sattar, N. , Harborne, L., Norman, J.E. and Fleming, R. (2008) The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. International Journal of Clinical Practice, 62(9), pp. 1337-1343. (doi: 10.1111/j.1742-1241.2008.01825.x)
Preiss, D. , Todd, L. and Panarelli, M. (2008) Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results. Annals of Clinical Biochemistry, 45(1), pp. 70-75. (doi: 10.1258/acb.2007.007100)
Preiss, D. and Sattar, N. (2008) Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical Science, 115(5-6), pp. 141-150.
2007
Preiss, D.J. , Godber, I.M., Lamb, E.J., Dalton, R.N. and Gunn, I.R. (2007) The influence of a cooked-meat meal on estimated glomerular filtration rate. Annals of Clinical Biochemistry, 44(1), pp. 35-42. (doi: 10.1258/000456307779595995)
Preiss, D.J. and Sattar, N. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? International Journal of Clinical Practice, 61(4), pp. 697-701. (doi: 10.1111/j.1742-1241.2007.01330.x)
2006
Preiss, D. and Sattar, N. (2006) Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence. Heart, 93(12), pp. 1493-1496. (doi: 10.1136/hrt.2007.130849)
Preiss, D.J. , Godber, I.M. and Gunn, I.R. (2006) How to measure renal function in clinical practice: Eating cooked meat alters serum creatinine concentration and eGFR significantly. British Medical Journal, 333(7577), p. 1072. (doi: 10.1136/bmj.39030.730949.3A)
Articles
Mayne, K. J. et al. (2023) Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease. Journal of the American Society of Nephrology, (doi: 10.1681/ASN.0000000000000271) (PMID:38082486) (Early Online Publication)
Coll, A. P. et al. (2020) GDF15 mediates the effects of metformin on body weight and energy balance. Nature, 578, pp. 444-448. (doi: 10.1038/s41586-019-1911-y) (PMID:31875646) (PMCID:PMC7234839)
Sattar, N. and Preiss, D. (2019) Research digest: new horizons in heart failure therapy. Lancet Diabetes and Endocrinology, 7(11), p. 832. (doi: 10.1016/S2213-8587(19)30315-8) (PMID:31621593)
Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)
Welsh, P. et al. (2019) Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes. Circulation, 139(24), pp. 2754-2764. (doi: 10.1161/CIRCULATIONAHA.118.038529) (PMID:31014085) (PMCID:PMC6571179)
Welsh, P. et al. (2018) Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clinical Chemistry, 64(11), pp. 1607-1616. (doi: 10.1373/clinchem.2018.292086) (PMID:30126950)
Sattar, N. , Toth, P. P., Blom, D. J., Koren, M. J., Soran, H., Uhart, M., Elliott, M., Cyrille, M., Somaratne, R. and Preiss, D. (2017) Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus. American Journal of Cardiology, 120(9), pp. 1521-1527. (doi: 10.1016/j.amjcard.2017.07.047) (PMID:28844508)
Sattar, N. and Preiss, D. (2017) Reverse causality in cardiovascular epidemiological research: more common than imagined? Circulation, 135(24), pp. 2369-2372. (doi: 10.1161/CIRCULATIONAHA.117.028307) (PMID:28606949)
Toth, P. P. et al. (2017) Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation, 135(19), pp. 1819-1831. (doi: 10.1161/CIRCULATIONAHA.116.025233) (PMID:28249876)
Preiss, D. et al. (2017) Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 19(3), pp. 356-363. (doi: 10.1111/dom.12826) (PMID:27862873) (PMCID:PMC5330429)
Schmidt, A. F. et al. (2017) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes and Endocrinology, 5(2), pp. 97-105. (doi: 10.1016/S2213-8587(16)30396-5) (PMID:27908689) (PMCID:PMC5266795)
Kristensen, S. L. et al. (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve). Circulation, 135(8), pp. 724-735. (doi: 10.1161/CIRCULATIONAHA.116.024593) (PMID:28052977)
Preiss, D. , Rankin, N. , Welsh, P. , Holman, R.R., Kangas, A.J., Soininen, P., Würtz, P., Ala-Korpela, M. and Sattar, N. (2016) Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study. Diabetic Medicine, 33(11), pp. 1569-1574. (doi: 10.1111/dme.13097) (PMID:26887663)
Preiss, D. and Sattar, N. (2016) Research digest: cardiac biomarkers for risk prediction. Lancet Diabetes and Endocrinology, 4(11), p. 890. (doi: 10.1016/S2213-8587(16)30293-5) (PMID:27743976)
Sattar, N. , Logue, J. and Preiss, D. (2016) Research digest: weight loss to prevent and treat diabetes. Lancet Diabetes and Endocrinology, 4(10), p. 817. (doi: 10.1016/S2213-8587(16)30244-3) (PMID:27663958)
Currie, G. et al. (2016) Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology, 17, 127. (doi: 10.1186/s12882-016-0337-0) (PMID:27609359) (PMCID:PMC5015203)
Preiss, D. and Sattar, N. (2016) Research digest: NAFLD in the spotlight. Lancet Diabetes and Endocrinology, 4(9), p. 735. (doi: 10.1016/S2213-8587(16)30187-5) (PMID:27480034)
Preiss, D. , Welsh, P. and Sattar, N. (2016) Metformin therapy and circulating NT-proBNP levels: the CAMERA trial. Diabetes Care, 39(8), e114-e115. (doi: 10.2337/dc16-0887) (PMID:27271181)
Sattar, N. and Preiss, D. (2016) Research digest. Lancet Diabetes and Endocrinology, 4(8), p. 651. (doi: 10.1016/S2213-8587(16)30161-9) (PMID:27401823)
Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J.V. (2016) SGLT2 and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1333-1339. (doi: 10.1007/s00125-016-3956-x) (PMID:27112340) (PMCID:PMC4901113)
Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J. (2016) Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1573-1574. (doi: 10.1007/s00125-016-3987-3) (PMID:27174369) (PMCID:PMC4969788)
Sattar, N. and Preiss, D. (2016) Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure. Lancet Diabetes and Endocrinology, 4(7), pp. 555-556. (doi: 10.1016/s2213-8587(16)30097-3) (PMID:27216887)
Sattar, N. and Preiss, D. (2016) Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing. Lancet Diabetes and Endocrinology, 4(7), pp. 560-562. (doi: 10.1016/S2213-8587(16)00085-1) (PMID:27039357)
Nissen, S. E. et al. (2016) Efficacy and tolerability of evolocumab vs. ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA: Journal of the American Medical Association, 315(15), pp. 1580-1590. (doi: 10.1001/jama.2016.3608) (PMID:27039291)
Loomis, A. K. et al. (2016) Body mass index and risk of non-alcoholic fatty liver disease: two electronic health record prospective studies. Journal of Clinical Endocrinology and Metabolism, 101(3), pp. 945-952. (doi: 10.1210/jc.2015-3444) (PMID:26672639) (PMCID:PMC4803162)
Goldie, C., Taylor, A. J., Nguyen, P., McCoy, C., Zhao, X.-Q. and Preiss, D. (2016) Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials. Heart, 102(3), pp. 198-203. (doi: 10.1136/heartjnl-2015-308055) (PMID:26370223)
Welsh, P. et al. (2016) Prediction of cardiovascular disease risk by cardiac biomarkers in 2 United Kingdom cohort studies: does utility depend on risk thresholds for treatment? Hypertension, 2016(67), pp. 309-315. (doi: 10.1161/HYPERTENSIONAHA.115.06501) (PMID:26667414) (PMCID:PMC4716288)
Kristensen, S. L. et al. (2016) Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure, 9(1), e002560. (doi: 10.1161/CIRCHEARTFAILURE.115.002560) (PMID:26754626) (PMCID:PMC4718182)
Jackson, C. E. et al. (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 18(12), pp. 1491-1498. (doi: 10.1002/ejhf.543) (PMID:27114189)
Rankin, N. J. , Preiss, D. , Welsh, P. and Sattar, N. (2016) Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future. International Journal of Epidemiology, 45(5), pp. 1351-1371. (doi: 10.1093/ije/dyw271) (PMID:27789671) (PMCID:PMC5100629)
Sattar, N. , Preiss, D. , Robinson, J. G., Djedjos, C. S., Elliott, M., Somaratne, R., Wasserman, S. M. and Raal, F. J. (2016) Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes and Endocrinology, 4(5), pp. 403-410. (doi: 10.1016/S2213-8587(16)00003-6) (PMID:26868195)
Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi: 10.1016/j.jchf.2015.03.014) (PMID:26251088)
Preiss, D. et al. (2015) Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 5(8), e007901. (doi: 10.1136/bmjopen-2015-007901) (PMID:26275900) (PMCID:PMC4550730)
Rush, C. J., Campbell, R. T., Jhund, P. S. , Connolly, E. C., Preiss, D. , Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC: Heart Failure, 3(8), pp. 603-614. (doi: 10.1016/j.jchf.2015.03.013) (PMID:26251086)
Yates, T. et al. (2015) Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabetic Medicine, 32(8), pp. 1090-1096. (doi: 10.1111/dme.12762) (PMID:25818859)
Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi: 10.1093/eurheartj/ehv072) (PMID:25802390) (PMCID:PMC4769322)
Preiss, D. and Kristensen, S. L. (2015) The new Pooled cohort equations risk calculator. Canadian Journal of Cardiology, 31(5), pp. 613-619. (doi: 10.1016/j.cjca.2015.02.001) (PMID:25843167)
Kristensen, S. L. et al. (2015) Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 17(2), pp. 169-176. (doi: 10.1002/ejhf.211) (PMID:25756844)
Preiss, D. and Sattar, N. (2015) Classification of reported statin intolerance. Current Opinion in Lipidology, 26(1), pp. 65-66. (doi: 10.1097/MOL.0000000000000149) (PMID:25551804)
Swerdlow, D. I. et al. (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, 385(9965), pp. 351-361. (doi: 10.1016/S0140-6736(14)61183-1) (PMID:25262344) (PMCID:PMC4322187)
Preiss, D. and Sattar, N. (2015) Does the LDL receptor play a role in the risk of developing type 2 diabetes? JAMA: Journal of the American Medical Association, 313(10), pp. 1016-1017. (doi: 10.1001/jama.2015.1275) (PMID:25756436)
Preiss, D. et al. (2014) Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 16(12), pp. 1265-1268. (doi: 10.1111/dom.12320) (PMID:24861892)
Welsh, P. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 57(12), pp. 2513-2520. (doi: 10.1007/s00125-014-3383-9) (PMID:25264116)
Preiss, D. (2014) Do statins reduce microvascular complications in diabetes? Lancet Diabetes and Endocrinology, 2(11), pp. 858-859. (doi: 10.1016/S2213-8587(14)70177-9) (PMID:25217179)
Preiss, D. , McMurray, J. J. and Sattar, N. (2014) Treatment of severe hypertriglyceridaemia. Lancet Diabetes and Endocrinology, 2(11), p. 860. (doi: 10.1016/s2213-8587(14)70052-x) (PMID:25439459)
Rankin, N. J. , Preiss, D. , Welsh, P. , Burgess, K. E.V., Nelson, S. M. , Lawlor, D. A. and Sattar, N. (2014) The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis, 237(1), pp. 287-300. (doi: 10.1016/j.atherosclerosis.2014.09.024) (PMID:25299963) (PMCID:PMC4232363)
Preiss, D. and Packard, C. J. (2014) Emerging therapeutic approaches to treat dyslipidemia. Current Cardiology Reports, 16(7), (doi: 10.1007/s11886-014-0506-3) (PMID:24890766)
Preiss, D. , Lloyd, S. M. , Ford, I. , McMurray, J. J.V. , Holman, R. R., Welsh, P. , Fisher, M., Packard, C. J. and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi: 10.1016/S2213-8587(13)70152-9) (PMID:24622715)
Sattar, N. , Forrest, E. and Preiss, D. (2014) Non-alcoholic fatty liver disease. British Medical Journal, 2014(349), g4596. (doi: 10.1136/bmj.g4596) (PMID:25239614) (PMCID:PMC4168663)
Preiss, D. and Sattar, N. (2013) Choice of medical therapy to lower triglycerides in those at risk of pancreatitis. Current Opinion in Lipidology, 24(6), pp. 532-533. (doi: 10.1097/MOL.0000000000000029)
Perez, A.C., Jhund, P. , Preiss, D. , Kjekshus, J. and McMurray, J.J.V. (2013) Effect of rosuvastatin on fatigue in patients with heart failure. Journal of the American College of Cardiology, 61(10), pp. 1121-1122. (doi: 10.1016/j.jacc.2012.12.004)
Preiss, D. (2013) Triglyceride levels, pancreatitis and choice of lipid-modifying therapy. Expert Review of Gastroenterology and Hepatology, 7(3), pp. 193-195. (doi: 10.1586/EGH.12.79)
Preiss, D. et al. (2013) Predictors of stroke in patients with impaired glucose tolerance: results from the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. Stroke, 44(9), pp. 2590-2593. (doi: 10.1161/STROKEAHA.113.001177)
Preiss, D. et al. (2012) Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2(6), e001925. (doi: 10.1136/bmjopen-2012-001925)
Preiss, D. et al. (2012) Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA: Journal of the American Medical Association, 308(8), pp. 804-811. (doi: 10.1001/jama.2012.8439)
Preiss, D. (2012) Statin therapy and new-onset diabetes: a cause for concern? Maturitas, 72(2), pp. 95-96. (doi: 10.1016/j.maturitas.2012.02.014)
Preiss, D. and Sattar, N. (2012) Pharmacotherapy: statins and new-onset diabetes—the important questions. Nature Reviews Cardiology, 9(4), pp. 190-192. (doi: 10.1038/nrcardio.2012.15)
Preiss, D. et al. (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 14(8), pp. 909-915. (doi: 10.1093/eurjhf/hfs067)
Sattar, N. and Preiss, D. (2012) HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. Diabetologia, 55(6), pp. 1564-1567. (doi: 10.1007/s00125-012-2510-8)
Ford, I. et al. (2011) The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International Journal of Epidemiology, 40(6), pp. 1530-1538. (doi: 10.1093/ije/dyr172)
Shyangdan, D., Clar, C., Ghouri, N. , Henderson, R., Gurung, T., Preiss, D. , Sattar, N. , Fraser, A. and Waugh, N. (2011) Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technology Assessment, 15(38), pp. 1-110. (doi: 10.3310/hta15380)
Preiss, D. , Sesashai, S.R.K. and Ray, K.K. (2011) Statin therapy dose and risk of new-onset diabetes: reply. JAMA: Journal of the American Medical Association, 306(12), p. 1326. (doi: 10.1001/jama.2011.1355)
Preiss, D. and Ray, K.K. (2011) Intensive glucose lowering treatment in type 2 diabetes. British Medical Journal, 343, d4243. (doi: 10.1136/bmj.d4243)
Ghouri, N. A. , Preiss, D. and Sattar, N. (2011) Reply (Need for a Three-Focused Approach to Nonalcoholic Fatty Liver Disease). Hepatology, 53(5), p. 1774. (doi: 10.1002/hep.24138)
Preiss, D. , Khunti, K. and Sattar, N. (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabetic Medicine, 28(1), pp. 19-22. (doi: 10.1111/j.1464-5491.2010.03157.x)
Preiss, D. and Sattar, N. (2011) The case for diabetes screening: ADDITION-Europe. Lancet, 378(9786), pp. 106-108. (doi: 10.1016/S0140-6736(11)60819-2)
Preiss, D. and Sattar, N. (2011) Statins and the risk of new-onset diabetes: a review of recent evidence. Current Opinion in Lipidology, 22(6), pp. 460-466. (doi: 10.1097/MOL.0b013e32834b4994)
Preiss, D. , Sattar, N. and McMurray, J.J. (2011) A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. American Heart Journal, 161(1), p. 210. (doi: 10.1016/j.ahj.2010.10.019)
Preiss, D. et al. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA: Journal of the American Medical Association, 305(24), pp. 2556-2564. (doi: 10.1001/jama.2011.860)
Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi: 10.1016/S0140-6736(09)61965-6)
Preiss, D. , Sattar, N. and McMurray, J.J. (2010) Event rates in trials of patients with Type 2 diabetes. JAMA: Journal of the American Medical Association, 303(8), pp. 732-733. (doi: 10.1001/jama.2010.137)
Ghouri, N. , Preiss, D. and Sattar, N. (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology, 52(3), pp. 1156-1161. (doi: 10.1002/hep.23789)
Preiss, D. and Sattar, N. (2010) HbA1c: a useful cardiovascular risk marker in those without diabetes? Diabetologia, 53(12), pp. 2468-2469. (doi: 10.1007/s00125-010-1902-x)
Preiss, D. , Welsh, P. , Murray, H., Shepherd, J., Packard, C. , Macfarlane, P., Cobbe, S., Ford, I. and Sattar, N. (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up(dagger). European Heart Journal, 31(10), pp. 1230-1236. (doi: 10.1093/eurheartj/ehq095)
Sattar, N. , Preiss, D. , Welsh, P. , Seshasai, S.R.K. and Ray, K.K. (2010) Statins and risk of incident diabetes Reply. Lancet, 375(9732), pp. 2141-2142.
Preiss, D. et al. (2009) Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920. (doi: 10.2337/dc08-1709) (PMID:19196892)
Preiss, D.J. and Sattar, N.A. (2009) Metformin and lactic acidosis Metformin: framed again? British Medical Journal, 339, b5570. (doi: 10.1136/bmj.b5570)
Preiss, D. and Sattar, N. (2009) Authors' reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. Clinical Endocrinology, 71(3), pp. 456-457.
Preiss, D. and Sattar, N. (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology, 70(6), pp. 815-828.
Preiss, D. and Sattar, N. (2009) Metabolic syndrome: collapsing under its own weight? Diabetic Medicine, 26(5), pp. 457-459.
Preiss, D. et al. (2009) Predictors of Development in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920.
Ray, K., Seshasai, S., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D. , Erqou, S. and Sattar, N. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 373(9677), pp. 1765-1772. (doi: 10.1016/S0140-6736(09)60697-8)
Preiss, D. , Sattar, N. , Harborne, L., Norman, J.E. and Fleming, R. (2008) The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. International Journal of Clinical Practice, 62(9), pp. 1337-1343. (doi: 10.1111/j.1742-1241.2008.01825.x)
Preiss, D. , Todd, L. and Panarelli, M. (2008) Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results. Annals of Clinical Biochemistry, 45(1), pp. 70-75. (doi: 10.1258/acb.2007.007100)
Preiss, D. and Sattar, N. (2008) Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical Science, 115(5-6), pp. 141-150.
Preiss, D.J. , Godber, I.M., Lamb, E.J., Dalton, R.N. and Gunn, I.R. (2007) The influence of a cooked-meat meal on estimated glomerular filtration rate. Annals of Clinical Biochemistry, 44(1), pp. 35-42. (doi: 10.1258/000456307779595995)
Preiss, D.J. and Sattar, N. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? International Journal of Clinical Practice, 61(4), pp. 697-701. (doi: 10.1111/j.1742-1241.2007.01330.x)
Preiss, D. and Sattar, N. (2006) Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence. Heart, 93(12), pp. 1493-1496. (doi: 10.1136/hrt.2007.130849)
Preiss, D.J. , Godber, I.M. and Gunn, I.R. (2006) How to measure renal function in clinical practice: Eating cooked meat alters serum creatinine concentration and eGFR significantly. British Medical Journal, 333(7577), p. 1072. (doi: 10.1136/bmj.39030.730949.3A)
Book Sections
Sattar, N. , Welsh, P. and Preiss, D. (2015) The insulin resistance syndrome. In: DeFronzo, R. A., Ferrannini, E., Alberti, K.G.M.M. and Zimmet, P. (eds.) International Textbook of Diabetes Mellitus. John Wiley & Sons, Ltd, pp. 337-353. ISBN 9781118387658 (doi: 10.1002/9781118387658.ch23)
Welsh, P. , Preiss, D. and Touyz, R. M. (2015) Biomarkers of hypertension and cardiovascular disease. In: Peplow, P., Adams, J. and Young, T. (eds.) Cardiovascular and Metabolic Disease: Scientific Discoveries and New Therapies. Series: RSC Drug discovery series. Royal Society of Chemistry, pp. 117-136. ISBN 9781782620464 (doi: 10.1039/9781782622390-00117)
Welsh, P. , Preiss, D. , Tsiropoulou, S., Rios, F. J. , Harvey, A., Dulak-Lis, M. G., Montezano, A. C. and Touyz, R. M. (2015) Biomarkers of vascular inflammation and cardiovascular disease. In: Berbari, A. and Mancia, G. (eds.) Arterial Disorders: Definition, Clinical Manifestations, Mechanisms and Therapeutic Approaches. Springer: Cham, pp. 115-136. ISBN 9783319145556 (doi: 10.1007/978-3-319-14556-3_9)